Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population.

Sci Rep · 2019 · PMC6499803 · PMID 31053747

Europe PMC DOI

hedged sentences

0.0620

closest p · 1.2× alpha

0.8800

boldest claim

The sentences

a decreasing trendp = 0.062so close (0.05 < p ≤ 0.1)

Changes in HbA1c and FBG from baseline among the different 4 groups Administration of dapagliflozin was found to reduce HbA1c significantly after 6 months by 1 percentage point (p = 0.045) and showed a decreasing trend after 12 months of 1.5 percentage points (p = 0.062).

also in 47,180 other papers

failed to reach statistical significancep = 0.88not close (p > 0.1)

With further analysis of data from follow-up at 9 and 12 months, the mean HbA1c was reduced by greater values, 1.1 ± 1.4%, and 1.5 ± 2%, respectively; however, these values failed to reach statistical significance (p = 0.88 & p = 0.63, respectively).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.